Best Bioprocess Podcasts (2024)

1
66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2 16:08

1d ago16:08

16:08

Get ready to dive into the fascinating world of cryopreservation! In this episode, we welcome Mark Davison, an experienced entrepreneur and CEO of Grant Instruments, leaders in laboratory equipment, to explore the intricate science of freezing and thawing cells. Mark brings his wealth of experience to demystify this crucial process, revealing how c…

1
Topical Ocular Biologics with Claris Bio's Clarke Atwell 58:06

2h ago58:06

58:06

We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that it's not the first to bring topically-administered biologic therapies to the front of the eye, but if succ…

1
65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1 24:15

3d ago24:15

24:15

Picture a world where we can freeze cells and bring them back to life perfectly intact. In this episode, we're joined by Mark Davison, a leading expert in cryopreservation and CEO of Grant Instruments to uncover the intricate science of freezing and thawing cells. From basic principles to advanced techniques, we delve into how cryopreservation is r…

1
C&G Regulatory Guidance with Lineage Therapeutics' Brian Culley 1:04:02

4d ago1:04:02

1:04:02

We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinical trial together, and did so despite lockdowns that kept a largely aged patient population from setting fo…

1
64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2 21:52

8d ago21:52

21:52

Could sound waves be the revolutionary key to gene therapy manufacturing? In this episode, Gabriel Dumy, CTO and Co-founder at Kolibri, reveals how acoustic waves are set to transform cell harvesting and gene transfection processes, making biomanufacturing more efficient and less damaging to cells. Kolibri is a company revolutionizing the way we gr…

1
63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1 25:27

10d ago25:27

25:27

Are sound waves the key to revolutionizing gene therapy? In this groundbreaking episode, we sit down with Gabriel Dumy, CTO and Co-founder at Kolibri, a company revolutionizing the way we grow and engineer cells at scale using acoustic waves. Gabriel shares the challenges facing modern bioproduction and unveils an exciting solution that's setting t…

1
True DEI Value in Biopharma with Arcellx's Rami Elghandour 1:04:08

11d ago1:04:08

1:04:08

We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate, and the promise of its AML, MDS, and solid tumor pipelines is attracting the kind of interest it takes to …

1
62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2 15:16

15d ago15:16

15:16

Dive into the future of bioprocessing with Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, as we explore how magnetic bead technology is transforming downstream processing. MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals. Key Ta…

1
61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1 19:22

17d ago19:22

19:22

Dive into the latest episode as we explore how magnetic bead technology is revolutionizing downstream processing, promising higher yields and greater purity. Our guest, Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, shares his insights on overcoming industry challenges and the future of purific…

1
Mission-Driven Dementia Funding with DDF's Jonathan Behr 55:46

18d ago55:46

55:46

We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-f…

1
60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2 20:37

22d ago20:37

20:37

Unlock the future of epigenetics and join us for an insightful conversation with Jonathon Hill as he delves into the groundbreaking world of next-generation sequencing (NGS) and its transformative impact on science and medicine. Jonathon Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Bio…

1
59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1 16:46

24d ago16:46

16:46

Curious about the latest advancements in next-generation sequencing (NGS) and how they are revolutionizing science and medicine? In this episode, we delve into the cutting-edge developments of NGS with our expert guest, Jonathon Hill, VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physio…

1
ADCs Ignited with Daiichi Sankyo Inc.'s Ken Keller 1:04:06

25d ago1:04:06

1:04:06

We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast forward to 2023, and we see an ADC arena that drove nearly $100 billion in M&A, licensing, and partnership …

1
58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2 19:08

29d ago19:08

19:08

Dive into the realm of biotech with our latest episode as we unravel the enigma of Quality by Design (QbD) with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines. Discover how integrating QbD principles early in your development cycle can revolutionize your approach to producing safe, high-quality …

1
57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1 17:14

1M ago17:14

17:14

Join us for an insightful episode as we dive into the world of bioprocess CMC development strategies with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines. Matthias shares his wealth of knowledge on avoiding common pitfalls in developing robust Chemistry, Manufacturing, and Controls (CMC) strategi…

1
Accelerating ADCs with Mythic Therapeutics' Brian Fiske, Ph.D. 56:38

1M ago56:38

56:38

We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls his many, and sometimes concurrent, early experiences as an MIT Ph.D. student, a Flagship Ventures Fellow, …

1
56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2 15:07

1M ago15:07

15:07

Is cultivated meat the food of tomorrow or just a passing trend? In this episode, we dive deep with Steven Lang, an expert in the field of cultivated meat. Steven sheds light on the intricate process of creating meat in the lab, the challenges faced, and the potential future of this innovative industry. Key Takeaways: Precision in Analytics: Discov…

1
55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1 22:45

1M ago22:45

22:45

How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange. Join us in this episode as we unravel the groundbreaking innovatio…

1
The Anti-CDMO with CTMC's Jason Bock, Ph.D. and KSQ's Thomas Leitch 57:35

1M ago57:35

57:35

We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's services aren't dissimilar from those offered by a contract developer, CTMC began with a more fundamental mission…

1
54: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 2 19:19

1M ago19:19

19:19

How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange. Join us in this episode as we unravel the groundbreaking innovatio…

1
53: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 1 18:20

2M ago18:20

18:20

How can you provide stress-free cultivation conditions to achieve higher cell concentrations and quality? In a nutshell, bionic bioreactors and thus change bubble-free gas exchange change the game. Join us as we delve into the future of biotech with our guest, Patrick Bongartz, CEO of BioThrust and an expert in innovative bioreactor design. Key Hig…

1
A New Prescription For PBMs with Allan Shaw 40:13

2M ago40:13

40:13

We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last, costly mile of the drug distribution supply chain. Allan pulls no punches in his criticism of the current …

1
52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2 25:41

2M ago25:41

25:41

Does the process of commercializing cell and gene therapies seem complex and unclear to you? Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therap…

1
51: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 1 19:26

2M ago19:26

19:26

Are you finding the path to commercializing cell and gene therapies complex and uncertain? Join us as we explore this intricate landscape with our guest, Wajiha Ali. As a strategy expert who believes in bridging the gap between research and commericalization with data who she will guide us through the challenges, victories, and vital strategies for…

1
New Apps For AI in mRNA With Anima Biotech's Yochi Slonim 59:10

2M ago59:10

59:10

We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a …

1
50: Decode Bioprocess Success: The Art of Stakeholder Management - Part 2 11:08

2M ago11:08

11:08

In the second part of "Decode Bioprocess Success: The Art of Stakeholder Management," we delve deeper into the strategies for effective stakeholder management in bioprocess development. Through a step-by-step approach, we explore how to identify, classify, and engage with stakeholders to ensure project success. Key highlights: Learn how to create a…

1
49: Decode Bioprocess Success: The Art of Stakeholder Management - Part 1 17:10

2M ago17:10

17:10

In this episode, we embark on a journey to uncover the essential strategies for navigating stakeholder relationships in bioprocess CMC development projects. We delve into the critical role of stakeholders in bioprocess development and how their engagement can determine the success or failure of a project. Drawing from real-life experiences and insi…

1
Circular RNA with Orna Therapeutics' Tom Barnes, Ph.D. and Advancing RNA's Anna Rose Welch 59:11

2M ago59:11

59:11

We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to co-host this week's episode. Together, Anna Rose and I press Dr. Barnes on his transition from academia to …

1
48: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 2 18:54

2M ago18:54

18:54

Unlock the secrets to cost-efficient antibody therapeutics with Brian Kelley, Senior Vice President of Process Development at VIR Biotechnology. In this illuminating episode, industry expert Brian Kelley shares invaluable insights into driving down manufacturing costs while maintaining quality and accessibility. From optimizing batch sizes to maxim…

1
47: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 1 16:55

2M ago16:55

16:55

Join us in this enlightening episode as we explore process economics with industry expert Brian Kelley. He is the Senior Vice President of Process Development at VIR Biotechnology. Unraveling the mysteries of cost management in antibody therapeutics, Brian sheds light on the intricate challenges faced by biotech scientists and engineers. Key Highli…

1
Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D. 1:01:30

2M ago1:01:30

1:01:30

We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital eve…

1
46: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 2 25:54

2M ago25:54

25:54

Dive into the future of food with our latest episode, "From Lab to Table: The Science Behind Cultivated Meat." With our guest, Petra Hanga, a Lecturer in Biochemical Engineering at University College London and Chief Scientific Officer of Quest Meat Ltd., we unravel the secrets behind this groundbreaking technology. Key highlights: 1. Discover how …

1
45: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 1 14:26

2M ago14:26

14:26

Dive into the fascinating world of cultivated meat with our guest, Petra Hanga, Lecturer in Biochemical Engineering – Cellular Agriculture at University College London and the Chief Scientific Officer of Quest Meat Ltd. In this episode, Petra sheds light on the intricacies of developing cultivated meat and reveals the key hurdles biotech scientists…

1
Commercial Readiness with ImmunityBio's Bobby Reddy, M.D. 56:54

3M ago56:54

56:54

We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team at ImmunityBio are doing to change that standard of care. They're painfully close. Dr. Reddy, Chief Medical…

1
44: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 2 18:26

3M ago18:26

18:26

Does uncovering the secrets of glycan engineering feel like navigating a maze of molecular complexity? In this captivating continuation of our exploration into the world of glycan engineering, we delve deeper into groundbreaking innovations and the crucial role of analytics in ensuring consistent quality. Henning von Horsten, Professor of Industria…

1
43: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 1 22:39

3M ago22:39

22:39

Does unlocking the secrets of glycan engineering seem like navigating a labyrinth of molecular complexity? In this episode, we delve into the pivotal role of glycans as critical quality attributes (CQAs) in biotherapeutics. Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), sheds li…

1
Precision Drug Delivery with Ampersand Biomedicines' Jason Gardner, D.Phil. 49:47

3M ago49:47

49:47

We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he's seen most of the ups and the downs that come with biotech leadership, and in his latest venture with th…

1
42: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 2 13:14

3M ago13:14

13:14

Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around. Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing o…

1
41: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 1 15:02

3M ago15:02

15:02

Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around. Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing o…

1
Funding Alzheimer's Tx Dev with ADDF's Karen Harris 40:16

3M ago40:16

40:16

We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. While the markets have warmed a bit since we recorded this episode, Karen's thoughtful perspective on the som…

1
40: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 2 14:57

3M ago14:57

14:57

Explore the intricate world of perfusion and its sustainability challenges in the part 2 of this episode. Dive into the operational side of managing vast quantities of media production and storage, and discover smart strategies to address these challenges. Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science, d…

1
39: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 1 23:53

3M ago23:53

23:53

Explore perfusion processes and sustainability with our guest, Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science. Learn about the evolution of perfusion methodologies, its historical roots in addressing product stability, and its recent return to continuous and integrated manufacturing. Jochen discusses the …

1
The AI Impact with Generate:Biomedicines' Mike Nally 1:13:54

3M ago1:13:54

1:13:54

We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish end of the spectrum is Flagship Pioneering's Generate Biomedicines, which bills itself at the "intersecti…

1
38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 2 16:41

3M ago16:41

16:41

In part 2 of this insightful episode, we embark on a journey into the intricate world of biotech purification processes. Our guest, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into three key modalities, shedding light on the challenges and advancements in virus, RNA, and traditional vaccine purification. You will …

1
37: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 1 19:38

3M ago19:38

19:38

In this episode, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into the complexities of purification. Wei’s team pioneers bioprocessing processes for diverse biotherapeutics. You will gain valuable insights into the intricate challenges and innovative solutions in bioprocessing purification. You will learn: Master s…

1
Strategic Deals with CinRx's Gavin Samuels, M.D. 47:52

3M ago47:52

47:52

We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't until he left the hospital and entered biopharma that he found his footing, cutting his teeth in business d…

1
36: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 2 17:30

4M ago17:30

17:30

Welcome back to the second part of our insightful interview with Joel Eichmann, Managing Director of Green Elephant Biotech. In this episode, we delve deeper into the technical aspects of adherent cell expansion systems, explore sustainable biotech practices, and discuss key considerations for cost-efficient and environmentally friendly bioprocessi…

1
35: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 1 18:46

4M ago18:46

18:46

Get ready for a deep dive into the world of bioprocess development as Joel Eichmann, Managing Director of Green Elephant Biotech, shares his expertise on smart strategies for adherent cell culture . Join us as we unravel the intricacies of adherent cell culture and discover the innovative strategies shaping the future of bioprocess development. You…

1
Serial Success With Triumvira's Rob Williamson 31:32

4M ago31:32

31:32

We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging around as many successful exits as Williamson has seen, one might become expert via osmosis. But Williamson is…

1
34: The 7 Habits of Highly Successful Innovators - Part 2 11:14

4M ago11:14

11:14

Uncover the secrets of successful innovators, including Steve Jobs, Elon Musk, and Thomas Edison, in this enlightening episode of our podcast. We dive deep into the habits that set these trailblazers apart and fuel their innovative spirit. Key learnings include: The power of curiosity and how it leads to groundbreaking ideas and improvements. The i…

Podcasts Worth a Listen

Bioprocess Podcasts

Podcasts Worth a Listen

Quick Reference Guide